In this segment, the panel focuses on clarifying terminology and discussing evolving treatment strategies for IgA nephropathy. They agree that “supportive therapy” is a more accurate and appropriate term than “conservative therapy” when describing foundational management approaches. The discussion then turns to the potential of emerging treatments, particularly B-cell modulators, which offer the ability to more directly address the underlying pathophysiology of the disease. These therapies may reduce pathogenic GD-IgA1 production, lower hematuria and proteinuria, and help slow the decline in kidney function—key goals in IgA nephropathy management. The speakers contrast these newer mechanism-targeted options with traditional therapies like RAAS inhibitors and SGLT2 inhibitors, which provide benefit but do not directly modify the drivers of disease. Overall, the panel highlights that newer therapies represent an important advancement, offering opportunities to more effectively intervene in the biological processes central to IgA nephropathy.